Logo

Marker Therapeutics, Inc.

MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that rec… read more

Healthcare

Biotechnology

21 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.90

Price

+0.48%

$0.01

Market Cap

$9.684m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$5.388m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$14.608m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.37

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$10.490m

$14.768m

Assets

$4.277m

Liabilities

-

Debt
Debt to Assets

0.00%

-

Debt to EBITDA
Free Cash Flow

-$10.884m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases